Gamma Delta T cells prove an exciting platform for the treatment of solid tumor indications and autoimmune disorders. The unique biology of these cells is revolutionizing the development of allogeneic therapies. 

The 5th rendition of the Gamma Delta T Cell Therapies Summit returns this year to take a deep dive into the biological intricacies of gamma delta T cells, deciphering the rich landscape of targeted interventions and engineering, and exploit their unique pathways and mechanisms to create more effective therapeutics. This is a great opportunity to help the community upskill their cross-functional team across discovery, translation and clinical development skills, to successfully translate basic research into your clinical strategy to support upcoming IND submissions. 

With a primary focus on streamlining clinical trial design for improved targeting of the TME, exploration of novel engineering strategies and appeasing regulatory bodies, we have collaborated with IN8Bio, Adicet Bio, Acepodia, Takeda, Luminary Therapeutics, LAVA Therapeutics, OneChain Therapeutics and many more expert companies to uncover the translational lessons learned in therapies focused on leveraging the inherent biological capabilities of gamma delta T cells. 

As the ONLY industry gamma delta T cell-specific meeting running this year, these three days will expedite the translation of your vd1/vd2 pipelines from bench to bedside, fostering prompt progress in the field.